text: SERVIRA - phenobarbital, hyoscyamine sulfate, atropine sulfate and scopolamine hydrobromide tablet, extended release - Prescription (RX) Marketed Drugs Encyclopedia
  You are here: Home > Prescription(RX) Drugs > S > Servira (Kylemore Pharmaceuticals, Llc)
  SERVIRA EXTENDED RELEASE TABLETS
  SERVIRA - phenobarbital, hyoscyamine sulfate, atropine sulfate and scopolamine hydrobromide tablet, extended release
  Each Servira Extended Release tablet contains:
  Phenobarbital, USP ........................................ 48.6 mg
  Hyoscyamine Sulfate, USP................................ 0.3111 mg
  Atropine Sulfate, USP........................................ 0.0582 mg
  Scopolamine Hydrobromide, USP .................... 0.0195 mg
  Servira Extended Release Tablets are designed to release the ingredients gradually to provide effects for up to twelve (12) hours.
  In addition, each tablet contains the following inactive ingredients: DC Yellow #10 Aluminum Lake, FDC Blue #1 Aluminum Lake, FDC Yellow #6 Aluminum Lake, Hydroxypropyl Methylcellulose, Lactose, Magnesium Stearate, PEG 3350, Polyvinyl Alcohol, Povidone, Silicon Dioxide, Stearic Acid, Talc, Titanium Dioxide.
  Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the following indications as "possibly" effective:
  Servira is contraindicated in patients with known hypersensitivity to any of the ingredients. Phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement.
  Servira may produce drowsiness or blurred vision. The patient should be warned, should these occur, not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery, and not to perform hazardous work.
  Animal reproduction studies have not been conducted with Servira. It is not known whether Servira can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Servira should be given to a pregnant woman only if clearly needed.
  It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Servira is administered to a nursing mother.
  The dosage of Servira should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse reactions. The usual dose is one tablet every twelve (12) hours. If indicated, one tablet every eight (8) hours may be given.
  The signs and symptoms of overdose are headache, nausea, vomiting, blurred vision, dilated pupils; hot and dry skin, dizziness, dryness of the mouth, difficulty in swallowing, CNS stimulation. Treatment should mconsist of gastric lavage, emetics, and activated charcoal. If indicated, parenteral cholinergic agents such as physostigmine or bethanechol chloride should be added.
  Servira Extended Release Tablets are supplied as: green, round tablets debossed "256", bottles of 100 tablets, NDC 49769-256-10.
  Servira Extended Release Tablet labeling:
  phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide tablet, extended release